The completion of SYMON-II enrollment and cash runway through Q2 2027 reduces near-term dilution risk, but the stock remains binary on FDA 510(k) clearance. Monitor for 510(k) submission timing and any clinical data readouts from SYMON-II, which are the primary catalysts.
Price Chart
Executive Summary
Bluejay Diagnostics reported Q2 2026 results, highlighting completion of SYMON-II pivotal study enrollment (750 patients) and a strengthened cash position of ~$9.6M (up from $5.2M at year-end 2025) following a $7.6M private placement. The company is advancing toward a 510(k) submission for its Symphony IL-6 sepsis test, with cash runway estimated through Q2 2027. No revenue was reported, and EPS data was not provided in the release, making this a clinical/regulatory update rather than a financial earnings event.
Key Facts
- SYMON-II pivotal study completed targeted enrollment of 750 patients
- Cash and cash equivalents of ~$9.6M at June 30, 2026, up from ~$5.2M at Dec 31, 2025
- Generated ~$7.7M net cash from financing in H1 2026, including ~$7.6M from June 2026 private placement
- Cash runway estimated through Q2 2027
- Company progressing toward FDA 510(k) submission for Symphony IL-6 test
- US manufacturing contract signed to mitigate supply-chain risk
- No revenue reported; pre-revenue clinical-stage diagnostics company
Financial Impact
Cash position strengthened to ~$9.6M, providing runway through Q2 2027; no revenue generated
Risk Factors
- FDA 510(k) clearance not guaranteed; regulatory denial would be value-destructive
- Pre-revenue with no approved products; cash burn continues
- Micro-cap with $1M market cap; extreme volatility and liquidity risk
- Competition from existing sepsis diagnostics and other IL-6 tests
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344302 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5600 (−32.72%) |
Oct 6, 2026 20d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5600 (−30.92%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5600 (−47.17%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5600 (−47.17%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5600 (−50.88%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5600 (−54.10%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5600 (−61.38%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5600 (+61.11%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5600 (+87.44%) |
Jun 9, 2026 19w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5600 (−87.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers